Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.
暂无分享,去创建一个
J. Molinuevo | J. Jovicich | G. Frisoni | C. Babiloni | R. Lizio | A. Soricelli | P. Visser | J. Wiltfang | S. Galluzzi | M. Marizzoni | G. Forloni | F. Nobili | M. Didic | R. Bordet | P. Payoux | L. Parnetti | P. Schönknecht | C. Ferrari | Lucia Boeri | Libera Cavaliere | Federica Fusco | I. Raimondi | L. Bocchio | P. M. Rossini | Diego Albani | Marco Salvatore | Magda Tsolaki | Jill C. Richardson | Olivier Blin
[1] C. Jack,et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.
[2] M. Chupin,et al. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers , 2018, Alzheimer's & Dementia.
[3] K. Blennow,et al. From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.
[4] D. Rujescu,et al. Amyloid blood biomarker detects Alzheimer's disease , 2018, EMBO molecular medicine.
[5] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[6] C. Rowe,et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.
[7] M. Fornage,et al. Associations of plasma clusterin and Alzheimer’s disease-related MRI markers in adults at mid-life: The CARDIA Brain MRI sub-study , 2018, PloS one.
[8] A. Saykin,et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study , 2018, PLoS medicine.
[9] Young Ho Park,et al. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.
[10] R. Dobson,et al. A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication , 2017, Journal of Alzheimer's disease : JAD.
[11] E. Umlauf,et al. Gender-related increase of tropomyosin-1 abundance in platelets of Alzheimer's disease and mild cognitive impairment patients. , 2017, Journal of proteomics.
[12] Q. Guo,et al. β-Amyloid Upregulates Intracellular Clusterin but not Secretory Clusterin in Primary Cultured Neurons and APP Mice. , 2017, Current Alzheimer research.
[13] Blaine R. Roberts,et al. A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort , 2017, Scientific Reports.
[14] P. Reddy,et al. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease , 2017, Human molecular genetics.
[15] E. Reiman,et al. Multivariate analyses of peripheral blood leukocyte transcripts distinguish Alzheimer's, Parkinson's, control, and those at risk for developing Alzheimer's , 2017, Neurobiology of Aging.
[16] M. Bondi,et al. Potential implications of practice effects in Alzheimer's disease prevention trials , 2017, Alzheimer's & dementia.
[17] C. Masters,et al. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals , 2017, Alzheimer's & dementia.
[18] James G. Bollinger,et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.
[19] P. Rossini,et al. CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUT-OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT , 2017, Alzheimer's & Dementia.
[20] P. Rossini,et al. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI) , 2017, Neurobiology of Aging.
[21] Magda Tsolaki,et al. Mitochondrial genes are altered in blood early in Alzheimer's disease , 2017, Neurobiology of Aging.
[22] C. Rowe,et al. Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort , 2017, Alzheimer's & dementia.
[23] Shunichiro Shinagawa,et al. Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer’s Disease and Amnestic Mild Cognitive Impairment , 2016, PloS one.
[24] K. Blennow,et al. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease , 2016, Alzheimer's & Dementia.
[25] D. Bennett,et al. Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer's disease pathology , 2016, Alzheimer's & Dementia.
[26] J. Molinuevo,et al. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’ , 2016, Journal of internal medicine.
[27] K. Blennow,et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease , 2016, Scientific Reports.
[28] C. Rowe,et al. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging , 2015, Alzheimer's & dementia.
[29] P. Lewczuk,et al. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. , 2014, Journal of Alzheimer's disease : JAD.
[30] Y. Takwoingi,et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2014, The Cochrane database of systematic reviews.
[31] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[32] O. Andreassen,et al. The role of clusterin in amyloid-β-associated neurodegeneration. , 2014, JAMA neurology.
[33] T. Lehtimäki,et al. Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort , 2013, PloS one.
[34] J. Trojanowski,et al. Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker , 2013, Alzheimer's Research & Therapy.
[35] J. Trojanowski,et al. Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients , 2012, Alzheimer's & Dementia.
[36] P. Koudstaal,et al. Plasma clusterin and the risk of Alzheimer disease. , 2011, JAMA.
[37] V. Pankratz,et al. Replication of CLU, CR1, and PICALM associations with alzheimer disease. , 2010, Archives of neurology.
[38] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[39] L. Kiemeney,et al. Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.
[40] K. Blennow,et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.
[41] B. Hyman,et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease , 2007, Neuroscience Letters.
[42] S. Lange,et al. Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.
[43] G. McLachlan,et al. Finite Mixture Models , 2000, Wiley Series in Probability and Statistics.
[44] Gastone G. Celesia,et al. A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .
[45] K. Blennow,et al. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.
[46] W. M. van der Flier,et al. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.